A phase II trial with tarenflurbil with mild to moderate AD showed a significant improvement in primary outcome of global functioning and activities of daily living, compared to placebo and a positive trend towards improved cognition.
← all excerpts
Current advances in the treatment of Alzheimer's disease: focused on considerations targeting Aβ and tau.
1
—
—